Eli Lilly and Company (LLY)
| Market Cap | 650.45B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 47.38 |
| Forward PE | 26.14 |
| Dividend | $6.00 (0.83%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 3,568,058 |
| Open | 724.12 |
| Previous Close | 714.59 |
| Day's Range | 717.08 - 729.00 |
| 52-Week Range | 623.78 - 937.00 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 972.00 (+34.15%) |
| Earnings Date | Oct 29, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $972.0, which is an increase of 34.15% from the latest price.
News
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines Gateway Labs model provides flexible lab space and tailored scientific engagement to supp...
Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.
Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announ...
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amy...
US FDA approves Eli Lilly's therapy for metastatic breast cancer
Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one lin...
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherap...
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Eli Lilly and Company (NYSE:LLY) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of In...
Eli Lilly: Buying The Dip With Confidence
Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing,...
Eli Lilly halts trial of experimental weight-loss drug
Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clin...
Lilly plans to launch its experimental weight-loss pill in India, exec says
Eli Lilly plans to bring its experimental oral weight-loss drug orforpligron in India as it sees scope for such products in the world's most populous nation, a senior executive said on Thursday.
The Big 3: AVGO, LLY, GS
@Theotrade's Don Kaufman is back on Big 3 — and is bearish on all of today's stocks. He points to exuberant A.I.
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improv...
Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas
The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday.
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
Eli Lilly said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of small molecule drugs, including its closely watched expe...
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines Company plans to create 4,615 manufactur...
Boys & Girls Clubs of America Receives $10 Million Grant from Lilly Endowment Inc. to Help Transform the Future of Youth Programs in and Around Native Communities
Funding will strengthen Boys & Girls Clubs serving youth who live on or near federal and state designated Native lands through program support, leadership development and digital transformation Fundin...
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million.
LLY & NVO Lead "Very Early Stages" of GLP-1 Market, PFE Reenters
Scott Zari says we're in the "very early stages" of the weight loss market. He points to Eli Lilly (LLY) as the market leader but notes Novo Nordisk (NVO) as a strong competitor, especially as it deve...
Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity
Eli Lilly is well-positioned for continued growth, driven by strong sales of Zepbound and Mounjaro in obesity and type 2 diabetes. Company is expanding Mounjaro's label to include children and adolesc...